36 assets in Thyroid Gland Carcinoma

Therapeutic assets addressing Thyroid Gland Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Palbociclib Thyroid Gland Carcinoma	University Medical Center Groningen	P4	BB (70)
Lenvatinib Thyroid Gland Carcinoma	University Medical Center Groningen	P4	BB (65)
Olaparib Thyroid Gland Carcinoma	University Medical Center Groningen	P4	BB (65)
Pazopanib Thyroid Gland Carcinoma	University Medical Center Groningen	P4	B (63)
Cetuximab Thyroid Gland Carcinoma	Institut de Recherches Internationales Servier	P1/2	CCC (54)
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- Thyroid Gland Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Binimetinib Thyroid Gland Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Capivasertib Thyroid Gland Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Crizotinib Thyroid Gland Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Dabrafenib Thyroid Gland Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Dasatinib Thyroid Gland Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Defactinib Thyroid Gland Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Fexagratinib Thyroid Gland Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Gsk-2636771 Thyroid Gland Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipatasertib Thyroid Gland Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Larotrectinib Thyroid Gland Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Thyroid Gland Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Osimertinib Thyroid Gland Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493 Thyroid Gland Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Pembrolizumab Thyroid Gland Carcinoma	Merck Sharp & Dohme LLC	P2	CCC (53)
Pertuzumab Thyroid Gland Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Relatlimab Thyroid Gland Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Sapanisertib Thyroid Gland Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Tislelizumab Thyroid Gland Carcinoma	SOLTI Breast Cancer Research Group	P2	CCC (53)
Trametinib Thyroid Gland Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Trastuzumab Thyroid Gland Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Trastuzumab Emtansine Thyroid Gland Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ulixertinib Thyroid Gland Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Vismodegib Thyroid Gland Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Adavosertib Thyroid Gland Carcinoma	National Cancer Institute (NCI)	P2	CCC (52)
Taselisib Thyroid Gland Carcinoma	National Cancer Institute (NCI)	P2	CCC (51)
Copanlisib Thyroid Gland Carcinoma	National Cancer Institute (NCI)	P2	CCC (49)
Panitumumab Thyroid Gland Carcinoma	Institut de Recherches Internationales Servier	P1/2	CCC (48)
s241656 Thyroid Gland Carcinoma	Institut de Recherches Internationales Servier	P1/2	CCC (48)
Spartalizumab Thyroid Gland Carcinoma	SOLTI Breast Cancer Research Group	P2	CC (46)
ik-595 Thyroid Gland Carcinoma	Ikena Oncology	P1	CC (43)